Reapplix A/S

Bregneroedvej 133, st., DK-3460 Birkeroed
CVR no. 31 26 15 70

Annual report for 2022

This annual report has been adopted at the company's annual general meeting on June 26, 2023

Chairman of the meeting:

Rikke Schiøtt Petersen

Rikke Schiøtt Petersen
Advokat
Gorrissen Federspiel
Advokatpartnerselskab
Axeltorv 2
1609 København V

Contents

Company information etc.	3
Management's review	4 – 5
Statement by the Board of Directors and the Executive Management on the annual report	6
Independent auditor's report	7 – 8
Consolidated income statement and statement of comprehensive income	9
Consolidated balance sheet	10
Consolidated statement of changes in equity	11
Consolidated cash flow statement	12
Consolidated notes	13 – 35
Parent Company income statement and statement of comprehensive income	36
Parent Company balance sheet	37
Parent Company statement of changes in equity	38
Parent Company cash flow statement	39
Parent Company notes	40 – 47

The company
Reapplix A/S
Bregneroedvej 133, st.
DK-3460 Birkeroed
CVR no.: DK 31 26 15 70

Bord of Directors
Richard Twomey, Chairman
Ulrik Spork
Bo Jesper Hansen
Tonni Bülow-Nielsen
Klaus Eldrup-Jørgensen
Søren Møller
Jørgen Ulrik Vejlsgaard
Cyrille Yann Nicolas Petit
Samuel Levy
Kira Paniagua Rupprecht

Executive Management
Morten Have-Rasmussen, CFO

Auditors
EY Godkendt Revisionspartnerselskab
Dirch Passers Allé 36
DK-2000 Frederiksberg
CVR no. 30 70 02 28

FINANCIAL REVIEW

The net result for the financial year 2022 was a loss of DKK 45 million compared to DKK 31.4 million in 2021. The increase is primarily due to higher US sales and marketing activities in 2022.

R&D
Research and development expenses totaled DKK 8.8 million in 2022 compared to DKK 9.8 million in 2021.

S&M
Sales and marketing expenses totaled DKK 39.4 million in 2022 compared to DKK 23.4 million in 2021. The increase was mainly due to higher activity levels in 2022.

General and administrative expenses
General and administrative expenses totaled DKK 6.8 million in 2022 compared to DKK 5.6 million in 2021. The expenses are at the same level as last year.

Financial items
Net financials totaled an income of DKK 5.4 million in 2022 compared to an expense of DKK 4.7 million in 2021. Financial expenses primarily cover foreing exchange losses.

Income tax benefit
Income tax benefit totaled DKK 1.6 million in 2022 compared to DKK 1.8 million in 2021. The Income tax benefit represents a tax credit for research and development expenses at the applicable tax rate under the Danish Corporate Income Tax Act.

Statement of financial position
As of December 31, 2022, the group had a cash balance of DKK 20.6 million compared to DKK 71.9 million as of December 31, 2021.

As of December 31, 2022, equity amounted to DKK 27.2 million compared with DKK 72.7 million as of December 31, 2021.

Cash flow
Net cash flow from operating activities amounted to an outflow of DKK 48.6 million in the year ended December 31, 2022 compared to DKK 36.9 million in the year ended December 31, 2021. Net cash flow from operating activities is attributable primarily to sales and marketing activities.

Net cash outflow from investing activities amounted to an outflow of DKK 5.3 million in the year ended December 31, 2022 compared to DKK 1.0 million in the year ended December 31, 2021. Investing activities comprise investment in equipment for demonstration purposes. as well as production equipment and software.

Net cash inflow from financing activities amounted to an outflow of DKK 0.019 million in the year ended December 31, 2022 compared to DKK 62.2 million in the year ended December 31, 2021. Financing activities comprise cash contributions from shareholders related to increase of share capital and lease payments.

Distribution of profit
The Board of Directors proposes that the loss for the year is transferred to retained earnings.

Subsequent events
No material events have arisen between the reporting date and the date of publication of the annual report that have not already been included in this annual report or have a material effect on the assessment of the Company's financial position.

In May 2023, a consortium consisting of new and existing investors agreed to a capital increase of DKK 77.8 million. The capital increase was paid out in May 2023 and introduces a new F-share class with liquidation preferences.

ABOUT REAPPLIX A/S

Reapplix has established that one of the keys to successful wound treatment lies in the body's capacity to heal – and each patient is central to that process.

Founded in 2008, Reapplix specializes in the biological treatment and management of diabetic foot ulcers. The patented 3CPatch® System is an annivative, evidence-based biological wound therapy made entirely from the patient's own blood – nothing else.

Headquatered in Denmark, with sales and distribution teams in the US and Europe, Reapplix won the 2018 EY Entrepreneur of the Year Award in the life science category.

Every wound is personal.

www.reapplix.com

Statement by Board of Directors and Executive Management on the annual report

The Board of Directors and the Executive Management have today considered and adopted the Annual Report of Reapplix A/S for the financial year January 1 – December 31, 2022 and the comparative figures for the financial year January 1 – December 31, 2021.

The consolidated financial statements and the parent company's financial statements are prepared in accordance with International Financial Reporting Standards as adopted by the European Union and additional disclosure requirements of the Danish Financial Statements Act. Management's Review has been prepared in accordance with the Danish Financial Statements Act.

In our opinion, the consolidated financial statements and the parent company financial statements give a true and fair view of the financial position of the Group and the Parent Company at December 31, 2022 and the comparative figures at December 31, 2021 and of the results of the Group's and Parent Company's operations and cash flows for the financial year January 1 – December 31, 2022 and the comparative figures for the financial year January 1 – December 31, 2021.

In our opinion, Management's Review includes a true and fair account of the development in the operations and financial circumstances of the Group and the Parent Company, of the results for the year and of the financial position of the Group and the Parent Company as well as a description of the most significant risks and elements of uncertainty facing the Group and the Parent Company.

We recommend that the Annual Report be adopted at the Annual General Meeting.

Birkeroed, June 26, 2023

Executive Management

DocuSigned by:
Morten Have-Rasmussen

Board of Directors

DocuSigned by:
Richard Twomey
Chairman

DocuSigned by:
Ulrik Spork
596AF9124067469...
Ulrik Spork

DocuSigned by:
876E0E551A9A4A9...
Cyrille Yann Nicolas Petit

DocuSigned by:
Samuel Levy

DocuSigned by:
Jørgen Ulrik Vejlsgaard
0A1863605C684EB...
Jørgen Ulrik Vejlsgaard

DocuSigned by:
2CB9734DF3C8462...
Søren Møller

DocuSigned by:
Bo Jesper Hansen
5CFE9320045843E...
Bo Jesper Hansen

DocuSigned by:
Tonni Bülow-Nielsen
C2FEC04B99E9458...
Tonni Bülow-Nielsen

DocuSigned by:
Klaus Eldrup-Jørgensen
51781D24F9EF42A...
Klaus Eldrup-Jørgensen

DocuSigned by:
Kira Paniagua Rupprecht
5FB5607701F8483...
Kira Paniagua Rupprecht

Independent auditor's report

To the shareholders of Reapplix A/S

Opinion

We have audited the consolidated financial statements and the parent company financial statements of Reapplix A/S for the financial year 1 January – 31 December 2022, which comprise income statement, statement of comprehensive income, balance sheet, statement of changes in equity, cash flow statement and notes, including accounting policies, for the Group and the Parent Company. The consolidated financial statements and the parent company financial statements are prepared in accordance with International Financial Reporting Standards as adopted by the EU and additional requirements of the Danish Financial Statements Act.

In our opinion, the consolidated financial statements and the parent company financial statements give a true and fair view of the financial position of the Group and the Parent Company at 31 December 2022 and of the results of the Group's and the Parent Company's operations and cash flows for the financial year 1 January – 31 December 2022 in accordance with International Financial Reporting Standards as adopted by the EU and additional requirements of the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the consolidated financial statements and the parent company financial statements" (hereinafter collectively referred to as "the financial statements") section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Group in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.

Statement on the Management's review

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on our procedures, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the Management's review.

Management's responsibilities for the financial statements

Management is responsible for the preparation of consolidated financial statements and parent company financial statements that give a true and fair view in accordance with International Financial Reporting Standards as adopted by the EU and additional requirements of the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Group's and the Parent Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Group or the Parent Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance,but is not a guarantee that an audit conducted in accordance with ISAs and additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit conducted in accordance with ISAs and additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's and the Parent Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's and the Parent Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and the Parent Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Copenhagen, June 26, 2023

EY Godkendt Revisionspartnerselskab
CVR no. 30 70 02 28

DocuSigned by:	DocuSigned by:
Kennet Hartmann	Anders Knudsen
09E6108BC0EC478...	5A0869292B8A4AF...
Kennet Hartmann	Anders Knudsen
State Authorised Public Accountant	State Authorised Public Accountant
mne40036	mne49064

Consolidated income statement and statement of comprehensive income

Note		2022 TDKK	2021 TDKK
5	Revenue	4,384	1,611
	Costs of sales	-1,511	-671
	Gross profit	**2,873**	**940**
6,7,10,11	Research and development expenses	-8,767	-9,834
6,7,10,11	Sales and marketing expenses	-39,357	-23,361
6,7,10,11	General and administrative expenses	-6,776	-5,590
	Operating loss	**-52,027**	**-37,845**
8	Financial income	5,655	5,004
9	Financial expenses	-227	-337
	Loss before tax	**-46,599**	**-33,178**
15	Income tax benefit	1,580	1,762
	Net loss for the period	**-45,019**	**-31,416**
	Other comprehensive loss to be reclassified to profit or loss in subsequent periods (net of tax):		
	Exchange differences on translation of foreign operations, net of tax	-2,379	-2,966
	Other comprehensive loss for the year, net of tax	**-2,379**	**-2,966**
	Total comprehensive loss	**-47,399**	**-34,382**
	Net loss attributable to:		
	Owners of the Parent Company	-45,019	-31,416
	Total	**-45,019**	**-31,416**
	Total comprehensive income attributable to:		
	Owners of the Parent Company	-47,399	-34,382
	Total	**-47,399**	**-34,382**

Note		2022 TDKK	2021 TDKK
	ASSETS		
	Non-current assets		
10	Intangible assets	874	558
11	Property, plant and equipment	7,244	4,861
	Deposits	322	422
	Total non-current assets	**8,440**	**5,840**
	Current assets		
12	Inventories	892	874
13	Trade receivable	2,056	183
15	Corporation tax receivable	1,598	1,762
	Other receivables	504	483
	Prepayments	702	691
	Cash and cash equivalents	20,641	71,890
	Total current assets	**26,393**	**75,883**
	TOTAL ASSETS	**34,833**	**81,723**
	EQUITY AND LIABILITIES		
	Equity		
14	Share capital	6,062	5,375
	Share premium	0	0
	Retained earnings	22,973	67,987
	Currency translation reserve	-3,007	-622
	Total equity	**26,028**	**72,740**
	Non-current liabilities		
16	Lease liabilities	910	664
	Total non-current liabilities	**910**	**664**
	Current liabilities		
16	Lease liabilities	511	600
	Bank debt	56	0
	Trade payables	907	1,386
15	Corporation tax payable	38	35
	Other payables and accruals	6,342	6,298
	Total current liabilities	**7,894**	**8,319**
	Total liabilities	**8,804**	**8,983**
	TOTAL EQUITY AND LIABILITIES	**34,833**	**81,723**

DocuSign Envelope ID: 67F99DA8-A5F9-439D-AC9C-7E4305341B23

	Note	Share capital TDKK	Share premium TDKK	Retained earnings TDKK	Currency translation reserve TDKK	Total TDKK
Equity as of January 1, 2021		**4,355**	**0**	**36,798**	**2,338**	**43,491**
Net loss for the period		0	0	-31,416	0	-31,416
Other comprehensive income for the period		0	0	0	-2,966	-2,966
Total comprehensive income		0	0	-31,416	-2,966	-34,382
Capital increase, cash injection	14	1,020	62,273	0	0	63,293
Transaction cost		0	0	0	0	0
Transfer to accumulated deficit		0	-62,273	62,273	0	0
Share-based payment expense	7	0	0	337	0	337
Equity as of December 31, 2021		**5,375**	**0**	**67,992**	**-628**	**72,739**

	Note	Share capital TDKK	Share premium TDKK	Retained earnings TDKK	Currency translation reserve TDKK	Total TDKK
Equity as of January 1, 2022		**5,375**	**0**	**67,992**	**-628**	**72,739**
Net loss for the period		0	0	-45,019	0	-45,019
Other comprehensive income for the period		0	0	0	-2,379	-2,379
Total comprehensive income		0	0	-45,019	-2,379	-47,398
Capital increase, cash injection	14	687	0	0	0	687
Share-based payment expense	7	0	0	0	0	0
Equity as of December 31, 2022		**6,062**	**0**	**22,973**	**-3,007**	**26,028**

Consolidated cash flow statement

	Note	2022 TDKK	2021 TDKK
Operating activities			
Loss before tax		-46,599	-33,178
Reversal of financial income	8	-5,655	-5,004
Reversal of financial expenses	9	227	337
Depreciation, amortization and impairment	10,11	3,259	2,331
Other non-cash items		960	1,966
Adjustments to reconcile loss before tax to cash flows from operating activities			
Share-based payment expense	7	0	337
Change in inventories		-18	-411
Change in trade receivables		-1,873	-31
Change in other receivables		-21	1,080
Change in prepayments		-11	-294
Change in trade payables		-479	-4,279
Change in other payables		44	-1,337
Cash flows from taxes	15	1,744	1,890
Interest paid	9	-227	-321
Net cash flow used in operating activities		**-48,648**	**-36,913**
Investing activities			
Investment in property, plant and equipment	10,11	-5,134	-1,034
Deposits		-114	0
Net cash flow used in investing activities		**-5,348**	**-1,034**
Financing activities			
Capital contributions from shareholders	14	687	63,293
Bank loans		56	-48
Lease payment		-762	-1,059
Net cash provided by financing activities		**-19**	**62,186**
Net change in cash and cash equivalents		**-53,915**	**24,238**
Net foreign exchange differences		2,666	30
Cash and cash equivalents at the beginning of the period		71,890	47,622
Cash and cash equivalents at the end of the period		**20,641**	**71,890**

1. Accounting policies
2. Significant accounting judgments, estimates and assumptions
3. Standards issued but not yet effective
4. Going concern
5. Revenue from contracts with customers
6. Employee benefit expenses
7. Share-based compensation expenses
8. Financial income
9. Financial expenses
10. Intangible assets
11. Property, plant and equipment
12. Inventories
13. Trade receivables
14. Shareholders' Equity
15. Income tax and deferred tax
16. Capital management
17. Contractual obligations and contingencies
18. Related party disclosures
19. Subsequent events

Corporate information

Reapplix A/S (the "Company") is a limited liability company incorporated and domiciled in Denmark. The registered office of Reapplix A/S is Bregnerødvej 133, st., 3460 Birkeroed, Denmark. In June 2018, a fully-owned subsidiary, Reapplix Inc., was incorporated in Delaware, USA (together with Reapplix A/S, "Reapplix" or the "Group"). In January 2020, a fully-owned subsidiary, Reapplix Limited was incorporated in Nottingham, UK (together with Reapplix A/S, "Reapplix" or the "Group")

The consolidated financial statements for the year ended December 31, 2022 were authorized for approval at the Annual General Meeting to be held on June 26, 2023, with a resolution of the Board of Directors on June 26, 2023.

1. Accounting policies

Basis of preparation

The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards, or IFRS, as adopted by the European Union and further requirements in the Danish Financial Statements Act.

The consolidated financial statements have been prepared on a historical cost basis except for share-based payment.

The consolidated financial statements are presented in Danish Kroner, or DKK, which is the functional currency of the Parent Company based on facts and circumstances and the technical requirements of IFRS. All values are rounded to the nearest thousand DKK where indicated.

Basis of consolidation

The consolidated financial statements comprise the financial statements of the Group and its subsidiary. Subsidiaries are those entities which are controlled by Reapplix. Reapplix controls an investment when Reapplix is exposed, or has rights, to variable returns from its involvement with the investment and has the ability to affect those returns through its power over the investment.

The financial statements of subsidiaries are consolidated from the date that control commences until the date that control ceases. The financial statements of subsidiaries are prepared for the same accounting period as Reapplix using consistent accounting policies.

On consolidation, intercompany balances, income, expenses, unrealized gains, and losses resulting from intercompany transactions are eliminated.

Foreign currency

Translation of foreign currency

On initial recognition, transactions denominated in foreign currencies are translated at the foreign exchange spot rate at the transaction date. Differences arising between the foreign exchange spot rates at the transaction date and the date of payment are recognized in the income statement as financial income or financial expenses.

Receivables, payables, and other monetary items denominated in foreign currencies are translated at the foreign exchange spot rates at the balance sheet date. The difference between the foreign exchange spot rates at the balance sheet date and the date at which the balance was recognized are recognized in the income statement as financial income or financial expenses.

Group companies

The assets and liabilities of foreign operations are translated into the presentation currency at the rate of exchange prevailing at the reporting date and their statements of profit or loss are translated at the monthly average exchange rates, unless the exchange rates fluctuate significantly in which case, the exchange rate at the date of transaction is applied. The exchange differences arising on translation for consolidation are recognized in other comprehensive income. On disposal of a foreign operation, the component of other comprehensive income relating to that foreign operation is recognized in the statement of profit or loss.

1. Accounting policies – continued –

Financial instrument valuation hierarchy

Financial instruments recognized at fair value are allocated to one of the following valuation hierarchy levels:

- Level 1: Quoted (unadjusted) prices in active markets for identical assets or liabilities.
- Level 2: Other techniques for which all inputs that have a significant effect on the recorded fair value are observable, either directly or indirectly.
- Level 3: Techniques that use inputs that have a significant effect on the recorded fair value that are not based on observable market data.

Management assessed that cash and short-term deposits, trade receivables, trade payables, and other current liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments.

Current versus non-current classification

The Group presents assets and liabilities in the statement of financial position based on current/non-current classification. An asset is classified as current when it is:

- expected to be realised or intended to be sold or consumed in the normal operating cycle
- held primarily for the purpose of trading
  or
- cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is classified as current when:

- it is expected to be settled in the normal operating cycle
- held primarily for the purpose of trading
- it is due to be settled within twelve months after the reporting period
  or
- there is an unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Group classifies all other liabilities as non-current. Deferred tax assets and liabilities are classified as non-current assets and liabilities.

Intangible assets

Intangible assets include software and are measured at cost less accumulated amortizations and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use. Amortization is calculated on a straight-line basis over the expected useful lives of the underlying assets. The useful life of and method of amortization of software are reviewed by management at least each year-end or more often based on changes in facts and circumstances. Changes in useful lives or residual values are adjusted prospectively as changes in accounting estimates.
The useful lives of software are finite. Software is amortized on a straight-line basis over a 5-year period.

Property, plant and equipment

Property, plant and equipment includes fixtures, fittings, demonstration equipment (centrifuges), right-of-use assets, and other plant and equipment, and are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use. Depreciation is calculated on a straight-line basis over the expected useful lives of the underlying assets. The residual values of equipment are not material. The useful life of and method of depreciation of equipment are reviewed by management at least each year-end or more often based on changes in facts and circumstances. Changes in useful lives or residual values are adjusted prospectively as changes in accounting estimates.

Demonstration equipment are centrifuges held by the sales force primarily for demonstration purposes. Centrifuges are depreciated on a straight-line basis over a 5-year period. Depreciation is recorded in sales and marketing expense. To the extent that demonstration equipment in the future will be sold on a regular basis, it will be reclassified to inventory.

1. Accounting policies – continued –

Property, plant and equipment are required to be tested for impairment when there are indications of impairment. Impairment tests are conducted at the individual asset level, or at the lowest level for which separately identifiable cash flows for groups of assets exist. Impaired assets or asset groups are written down to their recoverable amount, which is the higher of the value in use and the net realizable value of the asset or asset group, with impairment charges allocated proportionately to the assets within the impaired asset group.

Leases

The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Group's incremental borrowing rate. Generally, the Group uses its incremental borrowing rate as the discount rate.

Lease payments included in the measurement of the lease liability comprise the following:

- fixed payments, including in-substance fixed payments;
- variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date;
- amounts expected to be payable under a residual value guarantee; and
- the exercise price under a purchase option that the Group is reasonably certain to exercise, lease payments in an optional renewal period if the Group is reasonably certain to exercise an extension option, and penalties for early termination of a lease unless the Group is reasonably certain not to terminate early.

The lease liability is measured at amortised cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Group's estimate of the amount expected to be payable under a residual value guarantee, or if the Group changes its assessment of whether it will exercise a purchase, extension or termination option.

When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.

The Group presents right-of-use assets in 'property, plant and equipment' and lease liabilities in a separate line in the statement of financial position.

Short-term leases and leases of low-value assets

The Group has elected not to recognise right-of-use assets and lease liabilities for short-term leases of machinery that have a lease term of 12 months or less and leases of low-value assets, including IT equipment. The Group recognises the lease payments associated with these leases as an expense on a straight-line basis over the lease term.

1. Accounting policies – continued –

Corporation tax receivable

Corporation tax receivable is recognized in the balance sheet as the tax benefit computed on the taxable loss for the year, adjusted for any changes to the prior year benefit due to changes in the taxable loss of prior years and for any taxes already paid or refunded. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation or "uncertainty" and establishes provisions where appropriate. To date, there have been no provisions established for uncertain tax positions.

Deferred tax is measured using the balance sheet liability method on all temporary differences between the carrying amount and the tax value of assets and liabilities, with the exception of temporary differences occurring at the time of acquisition and liabilities neither effecting the result of operation nor the taxable income. The Group has no deferred tax balances as of December 31, 2022 or December 31, 2021.

For further details please refer to note 17.

Deposits

Deposits for property leased by the Group are measured at amortized cost.

Inventories

Inventories are measured at the lower of cost, in accordance with the weighted average price method, and the net realisable value. Provisions for obsolescence and remaining production and selling costs are deducted from the expected selling price, when estimating the net realisable value of inventories.

The cost of manufactured, finished and semi-finished products includes raw materials, direct labour, other production materials and production overheads. Production overheads include indirect labour and materials, repairs, maintenance and depreciation costs related to property, plant and equipment used in the production process, and costs related to production administration and management.

Financial assets

Classification and measurement

The Group initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs.

Subsequently, the Group measures its financial assets held based on the following measurement categories:

- Those to be measured at fair value through profit or loss,
- Those to be measured at amortised cost, and
- Those to be measured at fair value through other comprehensive income.

The classification is based on the company business model for managing the assets and the contractual terms of the cash flows. The new classification and measurement of the Group's financial assets are, as follows:

Receivables

Receivables from customers and other receivables are designated as receivables and are initially measured at fair value or transaction price and subsequently measured in the balance sheet at amortized cost, which generally corresponds to nominal value less expected credit loss provision. This is consistent with prior periods' classification.

Impairment

The Group record an allowance for expected credit losses for all loans and other debt financial assets not held at fair value through profit and loss. Expected credit losses are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive.

For receivables with customers and other receivables, the Group has applied the standard's simplified approach and has calculated expected credit losses based on lifetime expected credit losses. The provision for expected credit losses was not significant given that the Group has no history of credit losses and the nature of the Group's customers.

1. Accounting policies – continued –

Prepayments

Prepayments include expenditures related to future financial periods and are measured at nominal value.

Cash and cash equivalents

Cash includes cash on hand and in banks, as well as short term marketable securities that are subject to an insignificant risk of changes in value.

Equity

Direct and incremental costs associated with capital increases are accounted for as a reduction in the proceeds from the capital increase and recognized in shareholders' equity.

The translation reserve in the consolidated financial statements comprises foreign-exchange differences arising on translation of financial statements of Group entities from their local foreign currencies to the presentation currency used by the Group (DKK). On the disposal, entirely or partially, of a Group entity, the exchange-rate adjustment is recognized in profit or loss as a portion of the gain/loss on the sale.

Debt for equity swap with shareholders acting in its capacity as such are considered a capital contribution to the Group. Hence, these equity instruments are issued at the carrying amount of the financial liability extinguished so that no profit or loss is recognised.

Financial liabilities

The Group's financial liabilities historically have included lease liabilities, bank debt, trade payables and other payables.

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the effective interest rate method. Gains and losses are recognised in profit or loss when the liabilities are derecognised as well as through the effective interest rate amortisation process.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. The effective interest rate amortisation is included as finance costs in the statement of profit or loss.

Trade payables

Trade payables relate to the Group's purchase of products and services from various vendors in the normal course of business.

Other payables

Other payables are measured at net realizable value.

1. Accounting policies – continued –

Statement of Profit or Loss and Other Comprehensive Income

Revenue

The Group sells medical consumables through direct sales representatives and independent distributors. The Group recognizes revenue when control is transferred to the customer. For products sold through direct sales representatives and independent distributors, control is transferred upon shipment or upon delivery, based on the contract terms and legal requirements.

If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling price. Shipping and handling are treated as a fulfilment activity rather than a promised service, and therefore, is not considered a performance obligation. Taxes assessed by a governmental authority that are both imposed on, and concurrent with, a specific revenue producing transaction and collected by the Group from customers (for example, sales, use, value added, and some excise taxes) are not included in revenue.

The amount of revenue recognized reflects sales rebates and returns, which are estimated based on sales terms, historical experience, and trend analysis.

The Group includes obligations for returns in other accrued expenses in the consolidated balance sheets and the right-of-return asset in other current assets in the consolidated balance sheets. The right-of-return asset and right-of-return liability at December 31, 2022 and December 31, 2021 were not material.

The Group offers warranties on various products. For standard, assurance-type warranties, the Group estimates the costs that may be incurred under its warranties and records a liability in the amount of such costs at the time the product is sold.

The amount of the reserve is equal to the net costs to repair or otherwise satisfy the obligation. The Group includes the warranty obligation in other accrued expenses and other liabilities in the consolidated balance sheets.

Warranty obligations at December 31, 2022 and December 31, 2021 were not material.

Cost of sales

Cost of sales consists of variable production costs, including raw materials, other production materials and direct labour costs. In addition, cost of sales includes fixed production overhead costs such as indirect labour and materials, repairs, maintenance and depreciation costs related to property, plant and equipment used in the production process and costs related to production administration and management.

Public grants

The Group receives government grants from the Innovation Fund Denmark and from the Market Development Fund. These grants provide compensation for a part of certain project specific research and development expenses, including wages and salaries. Government grants are recognized where there is reasonable assurance that the grant will be received, and all attached conditions will be complied with.

Grants relating to expense items are recognized in the statement of profit or loss and set off against the related research and development expenses on a systematic basis over the periods that the related expenses for which it is intended to compensate are expensed.

Employee benefits

Employee benefits are primarily made up of salaries, share-based payment and pension. The cost of these benefits is recognized as expense as services are delivered. The Group's contributions to the employee pension plan have not been material.

Share-based payment

Employees and Management of the Group receive remuneration in the form of equity settled awards whereby services are rendered as consideration for warrants. The fair value of these equity-settled awards is determined at the date of grant resulting in a fixed fair value at grant date that is not adjusted for future changes in the fair value of the equity awards that may occur over the service period. Fair value of warrants and options is determined using the Black Scholes model.

1. Accounting policies – continued –

The cost of share-based payments is recognized as an expense together with a corresponding increase in equity over the period in which the performance and/or service conditions are fulfilled. In the event that equity instruments are granted conditionally upon an equal number of equity instruments granted in prior periods not being exercised, they are treated as a new grant for the current period and a modification of the equity instruments granted in the prior period.

The fair value of equity-settled awards is reported as compensation expense pro rata over the service period to the extent, such awards are estimated to vest. No cost is recognized for awards that do not ultimately vest.

When the terms of an equity-settled award are modified, the minimum expense recognised is the grant date fair value of the unmodified award, provided the original terms of the award are met. An additional expense, measured as at the date of modification, is recognised for any modification that increases the total fair value of the share-based payment transaction, or is otherwise beneficial to the holder. Where an award is cancelled by the entity or by the counterparty, any remaining element of the fair value of the award is expensed immediately through profit or loss.

Research and development expenses

Research and development expenses include salaries including share-based compensation and costs arising from research activities, clinical development, legal expenses related to the protection, defence and enforcement of the Group's intellectual property and rent associated with facilities used for research purposes. Given the uncertainty regarding the recoverability of clinical development costs, the Group has expensed all such expenses in the statement of loss and comprehensive loss for the periods presented.

Sales and marketing expenses

Sales and marketing expenses include salaries and costs arising from distribution of the Group's products including expenses related to marketing activities such as free trial periods with a fixed number of free kits.

General and administrative expenses

General and administrative expenses include salaries for administrative staff and management, costs of share-based payment and rent associated with facilities not used for research purposes.

Financial income and expense

Financial income and expense include interest income and expense, gains and losses due to changes in foreign exchange rates, allowances and surcharges related to the advance payment of tax scheme, and other miscellaneous items of financial income and expense.

Income tax benefit

The income tax for the period comprises current and deferred tax, including prior-year adjustments and changes in provisions for uncertain tax positions. Tax is recognized in the statement of profit or loss, except to the extent that it relates to items recognized in equity or in other comprehensive income.

Income tax also includes the current benefit due from the current period's taxable loss and deferred tax adjustments. The benefit is comprised primarily of refundable tax credits for costs incurred in connection with research and development activities under the Danish Tax Credit Regime.

Current tax payables and receivables are recognized in the balance sheet as a receivable in the event of prepayments and amounts due.

Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. Where the tax value can be determined according to alternative tax rules, deferred tax is measured on the basis of the planned use of the asset or the settlement of the obligation.

Deferred tax assets are measured at the value at which they are expected to be utilized, either through elimination against tax on future earnings or through a set-off against deferred tax liabilities. Deferred tax assets are set off within the same legal tax entity and jurisdiction.

1. Accounting policies – continued –

Subsequent events

If the Group receives information after the reporting period, but prior to the date of the Board of Directors' approval of the financial statements, about conditions that existed at the end of the reporting period, the Group assesses whether the information affects the amounts recognised in the financial statements. The Group will adjust the amounts recognised in the financial statements to reflect any adjusting events after the reporting period and update the disclosures that relate to those conditions in the light of the new information.

For non-adjusting events after the reporting period, the Group will not change the amounts recognised in the financial statements but will disclose the nature of the non-adjusting event and an estimate of its financial effect, or a statement that such an estimate cannot be made, if applicable.

Statement of cash flows

The statement of cash flows is presented using the indirect method and shows cash flows resulting from operating activities, investing activities, financing activities and the Group's cash and cash equivalents at the beginning and end of the year.

Cash flows used in operating activities primarily comprise the net loss for the year adjusted for non-cash items, such as foreign exchange gains and losses, depreciation, changes in working capital and cash received for interest and taxes.

Cash flows from investing activities are comprised primarily of investment in property, plant and equipment.

Cash flows from financing activities are comprised of repayment of bank debt and proceeds from capital increases net of transaction costs.

The preparation of the financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of income, expenses, assets and liabilities as well as the accompanying disclosures. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.

Judgments made in applying accounting policies

In the process of applying the Group's accounting policies, management has made the following judgments and estimates that have the most significant effect on the amounts recognized in the financial statements. Refer to the following notes for more details:

- Development projects
- Estimation of share-based compensation expenses (note 8)
- Judgment in respect of recognition of deferred taxes related to taxable losses to be carried forward (note 17).

Estimates and assumptions

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are listed below. The Group based its assumptions and estimates on information available when the financial statements were prepared.

2. Significant accounting judgments, estimates and assumptions

Judgement regarding accounting for development costs

Intangible assets arising from development projects should be recognised in the statement of financial position. The criteria that must be met for capitalisation are:

- The Group has the technical feasibility to complete the intangible asset so that it will be available for use or sale
- The Group intends to complete the intangible asset and use or sell it
- The Group has the ability to use or sell the intangible asset
- The intangible asset will generate probable future economic benefits. Among other things, the Group must demonstrate the existence of a market for the output of the intangible asset or the intangible asset itself or, if it is to be used internally, the usefulness of the intangible asset
- Adequate technical, financial and other resources must be available to complete the development and to use or sell the intangible asset
- The Group is able to reliably measure the expenditure attributable to the intangible asset during its development.

Such an intangible asset should be recognised if sufficient certainty can be documented that the future income from the development project will exceed the aggregate cost of production, development, and sale and administration of the product. In line with industry practice, due to both uncertainty and marketing approval by a regulatory authority the Group expenses all research costs as incurred.

Accordingly, the Group has not recognised such assets at this time. The total research and development costs related to operations amounted in the 12-months periods ended at December 31, 2022 and December 31, 2021 to DKK 9 million and DKK 10 million, respectively.

Estimation of share-based compensation expenses

The calculated fair value and subsequent compensation expenses for the Parent Company's share-based compensation are subject to significant assumptions and estimates. The fair value of warrants granted is calculated using the Black-Scholes option pricing model.

The key assumptions applied in determining fair value have been:
- Expected volatility
- Market share-price at grant year
- Expected future dividend yield per share
- Expected life of warrants in years
- Annual risk-free interest rate.

The expected volatility is based on peer group data and reflects the assumption that the historical volatility over a period similar to the life of the warrants is indicative of future trends, which may not necessarily be the actual outcome. The peer group consists of companies, which Management believes are similar to the Group in respect of similarity of product, geography and maturity.

The market share-price at grant year has, wherever possible, been determined as the implied fair value, which can be derived from the subscription price in the most recent and relevant capital increase round prior to granting the warrants. Where no capital increase has been carried out, at grant date, a fair value was estimated by considering a number of factors such as inflection points, valuations between independent parties etc.

The Parent Company does not expect to pay dividend in the foreseeable future.

The expected life of warrants, which is based on vesting terms, expected rate of exercise and life terms in the current warrant program.

The annual risk-free interest rate is based on a Danish government bond with the same maturity as the expected life of the warrants.

2. Significant accounting judgments, estimates and assumptions – continued –

The fair value of each warrant is based on unobservable input (level 3). The assumptions applied in determining fair value have been:

Market share-price at grant year	Share price for A class share (DKK)	Expected life of warrants in years*
2018	2.37	1
2019	65.7	1
2021	0	2-11
2022	0	2

** Expected life of warrants based on hold to maturity. If the Parent Company's shares are to be listed on a stock exchange or another regulated market, the warrants are exercisable prior to the listing.*

Judgement related to deferred taxes related to taxable losses to be carried forward

The Group recognizes deferred income tax assets if it is probable that sufficient taxable income will be available in the future against which the temporary differences and unused tax losses can be utilized. Management has considered future taxable income in assessing whether deferred income tax assets should be recognized and has concluded that the deferred income tax assets related to taxable losses to be carried forward do not meet the criteria for being recognized as assets in the statement of financial position.

The Group has net tax loss carry-forwards that are not recognized of DKK 21,672 thousand and DKK 19,896 thousand as of December 31, 2022 and December 31, 2021, respectively.

The Group's tax losses can be carried forward infinitely subject to the general rules on limited deductibility due to ownership changes.

Reference is made to note 15.

3. Standards issued but not yet effective

Reapplix Group has adopted relevant new or amended standards and interpretations as adopted by the EU and which are effective for the financial year 1 January – 31 December 2022. Reapplix Group has assessed that the new or amended standards and interpretations have not had any material impact on Reapplix Group's Annual Report in 2022.

At the date of authorisation of these financial statements, the Group has assessed the new and revised IFRS Standards that have been issued but are not yet effective. Based on the current business setup, none of the new standards or interpretations are expected to have a material impact on the Group's Annual Report.

4. Going concern

As of December 31, 2022, Reapplix held cash of DKK 20.6 million. In 2023, the Group expects to continue incurring substantial costs associated with the ongoing operational activities. In the opinion of Management, the cash available as of December 31, 2022, including cash from capital increase completed in May 2023, is sufficient for the Group's expected working capital needs for the next 12 months.

5. Revenue from contracts with customers

The Group's revenues are mainly derived from the 3C patch® system. The Group's primary customers include hospitals and clinics.

Reapplix A/S' registered office is situated in Denmark. The tables below illustrate revenue by geographical areas:

	2022 TDKK	2021 TDKK
Medical consumables (3CP™)		
Europe	460	608
United States of America (USA)	3,924	1,003
Total revenue	**4,384**	**1,611**

	2022 TDKK	2021 TDKK
Timing of revenue recognition		
Revenue from sale of Consumables at a point in time	4,384	1,611
Total revenue	**4,384**	**1,611**

Summary of key performance obligations related to revenue streams

Below the key performance obligations regarding sale of medical consumables are summarized.

Revenue streams	Performance obligations	When performance obligations are met and the timing of satisfaction of performance obligations	Significant payment terms	Nature of goods and services promised	The allocation of transaction price to performance obligations
Sale of medical consumables.	The Group typically satisfies its performance obligations upon shipment or upon delivery of the medical consumables.	Performance obligations are satisfied at a point in time when the Group has a present right to payment for medical consumables and when the customers have legal title to the asset.	The consideration is usually fixed. Customers have 30-90 days payment terms from invoice date.	The goods promised primarily comprise the medical consumables (3CP™).	The transaction prices are stand-alone selling prices of the respective promised medical consumables.

6. Employee benefit expenses

	2022 TDKK	2021 TDKK
Staff costs		
Wages/salaries	32,053	18,382
Share-based compensation expenses (note 7)	0	337
Other social security costs	1,760	1,771
Other staff costs	0	249
Total staff costs	**33,813**	**20,739**
Average number of employees during the year	24	16
Executive management remuneration		
Wages/salaries	3,148	4,453
Share-based compensation expenses (note 7)	0	337
Other social security costs	42	7
Other staff costs	0	51
Total executive management remuneration	**3,190**	**4,848**
Board of Directors remuneration		
Remuneration to the Board of Directors	916	980
Total Board of Directors remuneration	**916**	**980**
Total staff costs are included within the income statement as follows:		
Cost of sales	790	418
Research and development expenses	5,007	4,922
Sales and marketing expenses	24,326	11,529
General and administrative expenses	3,690	3,869
Total staff costs	**33,813**	**20,739**

The amounts disclosed in the table above are the amounts recognized as an expense during the reporting periods. Executive Management consists of the Group's Chief Scientific Officer and Chief Financial Officer. See note 18 for compensation paid to the members of the Board of Directors.

7. Share-based compensation expenses

The Group has issued warrants to employees, the Executive Management and Board of Directors. The warrants can be settled by subscribing for A-shares of Reapplix A/S at an exercise price in the range of DKK 48 – DKK 64 per share. At time of grant the vesting period was in the range of 0 – 36 months.

The table below summarizes the activity related to the warrants for the 12-months period ended December 31, 2022 and the 12-months period December 31, 2021:

7. Share-based compensation expenses – continued –

	Executive Management	Key Employees	Board of Directors	Other	Total warrants
Outstanding at January 1, 2021	**208,137**	**0**	**105,520**	**0**	**313,657**
Granted	0	0	62,020	0	62,020
Expired	-20,977	0	-45,000	0	-65,977
Outstanding at December 31, 2021	**187,160**	**0**	**122,540**	**0**	**309,700**
Granted	68,683	0	0	0	68,683
Expired	-127,160	0	-60,520	0	-187,680
Transferred	-22,894	22,894	-60,520	60,520	0
Outstanding at December 31, 2022	**105,789**	**22,894**	**1,500**	**62,020**	**190,703**

The Group has granted warrants to the Executive Management and Board of Directors that may only be exercised if and to the extent that warrants issued earlier have not been exercised (warrants running in parallel). All warrants granted are included in the table above. A number of exercisable warrants are running in parallel, meaning that the net exercisable number of warrants are 160,703 as of December 31, 2022 (December 31, 2021: 219,180).

The weighted average remaining contractual life of the warrants outstanding as of December 31, 2022 and December 31, 2021 was 0,4 year and 1 years, respectively.

The weighted average exercise prices of the warrants outstanding as at December 31, 2022 and December 31, 2021 were 54,68 and 54,65, respectively.

Share-based compensation recognised in the income statement:

	2022 TDKK	2021 TDKK
Research and development expenses	0	0
General and administrative expenses	0	337
Total share-based compensation recognized in the income statement	**0**	**337**

For further details regarding significant estimates made by Management, while measuring the fair value of share-based compensation, reference is made to note 2.

8. Financial income

	2022 TDKK	2021 TDKK
Foreign exchange gain	5,651	5,003
Other interest income	4	1
Total financial income	**5,655**	**5,004**

9. Financial expenses

	2022 TDKK	2021 TDKK
Foreign exchange losses	0	16
Interest expenses, lease liabilities	139	142
Other interest expenses	88	179
Total financial expenses	**227**	**337**

10. Intangible Assets

	Software TDKK
Cost at January 1, 2021	362
Cost at December 31, 2021	668
Additions	388
Disposals	0
Cost at December 31, 2022	1,056
Accumulated depreciation at January 1, 2021	36
Accumulated depreciation at December 31, 2021	110
Depreciation expense	72
Accumulated depreciation at December 31, 2022	182
Total net carrying value at:	
December 31, 2021	558
December 31, 2022	874

10. Intangible Assets – continued –

Depreciation expense

Depreciation expense is included in the income statement as follows:

	2022 TDKK	2021 TDKK
Research and development expenses	29	30
Sales and marketing expenses	14	14
General and administrative expenses	29	30
Total depreciation expense	**72**	**74**

11. Property, plant and equipment

	Fixtures and fittings, other plant and equipment TDKK	Right-of-use assets TDKK	Demonstration equipment TDKK	Total TDKK
Cost at January 1, 2021	590	3,643	5,788	10,021
Currency adjustment	69	0	0	69
Additions	65	184	665	914
Disposals	0	0	-66	-66
Cost at December 31, 2021	724	3,827	6,387	10,938
Currency adjustment	0	0	70	70
Additions	422	822	4,334	5,578
Disposals	-540	-589	0	-1,129
Cost at December 31, 2022	606	4,060	10,791	15,457
Accumulated depreciation at January 1, 2021	548	1,891	1,717	4,156
Currency adjustment	-39	0	0	-39
Depreciation expense	42	765	1,196	2,003
Write-down	0	0	0	0
Disposals	0	0	-43	-43
Accumulated depreciation at December 31, 2021	551	2,656	2,870	6,077
Currency adjustment	0	-7	0	-7
Depreciation expense	80	572	1,335	1,987
Write-down	0	1,182	0	0
Disposals	-437	-589	0	-1,026
Accumulated depreciation at December 31, 2022	194	3,815	4,205	7,031
Total net carrying value at:				
December 31, 2021	173	1,171	3,517	4,861
December 31, 2022	412	246	6,586	8,426

11. Property, plant and equipment – continued –

Right-of-use assets
The Group has entered into a lease agreement for its domicile, including equipment in Birkeroed, Denmark and office in the US.

For 2022, and 2021, the Group recognized an expense of DKK 48 thousand and DKK 57 thousand respectively, relating to short-term leases and leases of low value assets.

Depreciation expense

Depreciation expense is included in the income statement as follows:

	2022 TDKK	2021 TDKK
Cost of sales	124	78
Research and development expenses	600	1,065
Sales and marketing expenses	957	671
General and administrative expenses	305	189
Total depreciation expense	**1,987**	**2,003**

12. Inventories

	2022 TDKK	2021 TDKK
Raw materials and packaging	475	283
Finished goods	417	591
Total inventories	**892**	**874**

The total amount of inventories recognized as an expense in the 12-months periods ended at December 31, 2022 and December 31, 2021 amounted to DKK 378 thousand and DKK 408 thousand, respectively.

No write-down or reversal of write-down during the reporting periods.

13. Trade receivables

The following table summarizes the Group's trade receivables:

TDKK	**Loss procent**	**Receivables**	**Expected loss**	**Total**
31 December 2022				
Not past due	0.0%	537	0	537
Overdue 1 to 30 days	0.0%	335	0	335
Overdue 31 to 60 days	0.0%	206	0	206
Overdue 61 to 90 days	0.0%	209	0	209
Overdue with more than 90 days	55.3%	1,723	954	769
		3,010	**954**	**2,056**
31 December 2021				
Not past due	71.1%	399	284	115
Overdue 1 to 30 days	0.0%	0	0	0
Overdue 31 to 60 days	85.7%	330	283	47
Overdue 61 to 90 days	0.0%	0	0	0
Overdue with more than 90 days	0.0%	21	0	21
		750	**567**	**183**

13. Trade receivables – continued –

Credit risk on trade receivables
The Group performs credit risk assessments of the customers on a regular basis. Managing the credit risk of customers is based on internal credit ratings on customers. The credit limit is determined based on the individual customer's credit assessment and local market risks.

The Group uses a simplified expected credit loss model to the assessment of privision for impairment of financial assets measured at amortised cost including trade receivables. The model recognises the loss in total comprehensive income over the assets useful lifetime when the loss is expected and subsequently monitored by management according to the Group's risk policy until realisation of the loss. The impairment loss is calculated based on an expected loss percentage considering the individual customers.

14. Shareholders' equity

The following table summarizes the Company's share activity:

DKK	Class A ordinary shares	Class B preferred shares	Class C preferred shares	Class D preferred shares	Class E preferred shares	Total
January 1, 2021	**203,020**	**98,930**	**211,347**	**2,305,596**	**1,536,178**	**4,355,071**
Capital increase, cash injection					1,020,016	1,020,016
December 31, 2021	**203,020**	**98,930**	**211,347**	**2,305,596**	**2,556,194**	**5,375,087**
Capital increase, cash injection					687,301	687,301
December 31, 2022	**203,020**	**98,930**	**211,347**	**2,305,596**	**3,243,495**	**6,062,388**

On December 31, 2022 and December 31, 2021, the share capital of the Company comprised 6,062,388 shares and 5,375,087 shares, respectively with a nominal value of DKK 1 each. Each share entitles the holder to cast one vote at general meetings in the Company.

The share capital of the Company is divided into share classes entitled to liquidation preferences in the following order:

Share class	Number of shares	Nominal value per share (DKK)	Liquidation preference order	Ref.
Class A	203,020	1	5th	
Class B	98,930	1	4th	
Class C	211,347	1	3rd	
Class D	2,305,596	1	2nd	a)
Class E	3,243,495	1	1st	
Total	**6,062,388**			

(E) Firstly, an amount equal to the actual subscription amount paid for the E shares shall be paid to the holders of E shares.

(B-D) Secondly, an amount up to DKK 247,361,015 (adjusted in case of changes to number and/or preferences allotted to the B.– E share classes) shall be distributed with a) 35,6% to the holders of E shares and b) 64,5% to the holders of D, C, and B shares. The amount to be paid the holder of D, C and B share shall be paid in the following order:

- i) an amount equal to the subscription amount paid for the D shares plus DKK 13,911,228 shall be paid to the holders of D shares, then
- ii) an amount equal to the subscription amount paid for the C shares plus DKK 4,449,070 shall be paid to the holders of C shares, then
- iii) an amount equal to the subscription amount paid for the B shares plus DKK 1,639,702 shall be paid to the holders of B shares

(A-E) Finally, any remaining distribution of funds shall be made pro rata among all the shareholders (according to nominal share values).

15. Income tax and deferred tax

	2022 TDKK	2021 TDKK
Current tax on benefit on net loss	9,607	5,600
Adjustment to prior years	330	0
Tax credit research and development expenses	1,598	1,762
Provision for income tax	-18	0
Change in unrecognized deferred tax before tax credit	-9,937	-5,600
Total income tax benefit for the period	**1,580**	**1,762**

Reconciliation of effective tax rate to Danish statutory tax rate

	December 31, 2022 TDKK	December 31, 2021 TDKK
Net loss before tax	46,599	33,178
Corporate income tax rate in Denmark	22%	22%
Computed income tax benefit	**10,252**	**7,299**
Tax effect of:		
Effect of (higher)/lower tax rates in foreign subsidiaries	321	157
Adjustment to prior years	330	0
Provision for income tax	-18	-35
Other non-deductible expenses, including share-based compensation	-178	-588
Increased tax deductions on research and development expenses	479	529
Deferred tax asset not recognized	-9,607	-5,600
Total income tax benefit for the period	**1,580**	**1,762**

	2022 TDKK	2021 TDKK
Corporation tax receivable at January 1	1,762	1,896
Received corporate tax during the financial year	-1,762	-1,896
Calculated corporate tax current year	1,598	1,762
Transferred from non-current	0	0
Corporation tax receivable (current)	**1,598**	**1,762**

Deferred tax in the statement of financial position

	December 31, 2022 TDKK	December 31, 2021 TDKK
Deductible tax losses	38,052	29,249
Other temporary differences	1,053	218
	39,074	29,467
Deferred tax asset not recognized	-39,074	-29,467
Carrying amount	**0**	**0**

The Company had net tax loss carry-forwards in Denmark for income tax purposes of DKK 38,052 thousand and DKK 29,249 as of December 31, 2022 and December 31, 2021.

Income tax benefit for the year includes a tax credit for research and development at the applicable tax rate under the Danish Corporate Income Tax Act.

15. Income tax and deferred tax – continued –

The tax loss carry-forwards has no expiry date. The Company's ability to use tax loss carry-forwards in any one year is limited to 100% of the first DKK 8.9 million of taxable income plus 60% of taxable income above DKK 8.9 million.

The Company recognizes deferred tax assets, including the tax base of tax loss carry-forwards, if Management assesses that these tax assets can be offset against positive taxable income within a foreseeable future. Significant management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies. This judgment is made periodically after considering current facts and circumstances, budgets and business plans as well as the risks and uncertainty associated with the Company's ability successfully to commercialize and defend its intellectual property.

Significant judgment

The development of medical devices and launching such devices within the life sciences industry are subject to significant risks and uncertainties and there is no assurance that a medical device will be successfully developed or commericalized. As the result of this uncertainty and since the Company has reported significant losses since inception, has limited commercial products or revenues, Management has concluded that deferred tax assets should not be recognized as of December 31, 2022 or at any other prior date. The tax assets are currently not deemed to meet the criteria for recognition as Management is not able to provide virtually certain evidence that taxable profits will be available in the future to utilize the benefit from the tax assets.

As of December 31, 2022, there are no tax audits in process nor has Management been notified of any pending tax audit.

16. Capital management

For the purpose of the Group's capital management, capital includes issued capital and all equity reserves. The primary objective of the Group's capital management is to maximize shareholder value. The Board of Directors' policy is to maintain a strong capital base to maintain investor, creditor and market confidence, and a continuous advancement of the Group's intellectual property, product pipeline and business. Cash, cash equivalents and financial assets are monitored on a regular basis by Management and the Board of Directors in assessing current and long-term capital needs. As of December 31, 2022 the Group held cash and cash equivalents totaling DKK 20.6 million that will be sufficient to provide adequate funding to allow the Group to meet its planned operating activities in the normal course of business for the 12-months period ending December 31, 2022.

Through its activities the Group is exposed to a number of financial risks whereby future events, which can be outside the control of the Group, could have a material effect on the Group's financial position and results of operations. The known risks include foreign currency, interest, credit and liquidity risk and there could be other risks currently unknown to Management. Historically, the Group has not hedged its financial risks.

Foreign currency

The Group maintains operations in Denmark and in the United States of America and uses the DKK as its functional currency in Denmark and US Dollars (USD) in the US. The Group conducts cross-border transactions where the functional currency is not always used. Accordingly, future changes in the exchange rates of the DKK and/or the USD will expose the Group to currency gains or losses that will impact the reported amounts of assets, liabilities, income and expenses and the impact could be material. For the years ended December 31, 2022 and December 31, 2021, the impact on the Group's income statement of possible changes in the USD exchange rates against the Parent Company's functional currency of DKK would be as follows:

Currency	**Possible change**	**2022 TDKK**	**2021 TDKK**
USD	+/-10%	(3,210) / + 3,210	(1,520) / +1,520

Interest rate risk

In all material aspects, the Group's only interest-bearing debt is lease liabilities.

Credit risk

The credit risk is the risk that a counterpart to the Group do not fulfil their responsibility towards the Group. The Group is exposed for the credit risk of their customers if a sale is completed without a payment in advance because a receivable incur against the customer. Reference is made to note 11 for further description of credit risk on trade receivables.

16. Capital management – continued –

Managing the credit risk related to the Group's customers is controlled by the Group.

The Group's credit risk is associated with cash held in banks. The Group does not trade financial assets for speculative purposes and invests with the objective of preserving capital.

Liquidity risk

The Group's liquidity risk covers the risk that the Group is not able to meet its liabilities as they fall due.

The maturities of the financial liabilities are stated in the tables below. All amounts are contractual cash flows, i.e. inclusive of interest.

	Within 1 year	1 – 2 year(s)	2 – 5 years	Over 5 years	Total
Liabilities as at December 31, 2022					
Lease liabilities	667	683	439	0	1,789
Trade payables	907	0	0	0	907
Total	**1,574**	**683**	**439**	**0**	**2,696**

	Within 1 year	1 – 2 year(s)	2 – 5 years	Over 5 years	Total
Liabilities as at December 31, 2021					
Lease liabilities	667	683	439	0	1,789
Trade payables	1,386	0	0	0	1,386
Total	**2,053**	**683**	**439**	**0**	**3,175**

Fair value

The carrying value of financial assets and financial liabilities measured at amortized cost is considered not to differ significantly from the fair value.

There were neither assets nor liabilities measured at fair value as of December 31, 2022 or December 31, 2021.

17. Contractual obligations and contingencies

Contingencies are assets and liabilities that arise from past events but whose existence will only be confirmed by the occurrence or non-occurrence of future events that in some situations are beyond the Group's control. As of December 31, 2022, and 2021 there are no contingent assets or liabilities.

18. Related party disclosures

The Group's related parties comprise the subsidiary of the Parent Company, the significant shareholders of the Company and their subsidiaries, the Executive Management, the Other-key-management, the Board of Directors and close members of the families of these persons.

All intercompany transactions between the Parent Company and the subsidiaries have been eliminated in the consolidated financial statements.

	2022 TDKK	2021 TDKK
Transactions with related parties		
Lease of domicile, including equipment from N. E. Holm A/S	684	1,036
Purchase of goods from Innoventa Medica ApS	257	902
Purchase of other services from N. E. Holm A/S	0	258

18. Related party disclosures – continued –

In 2008, the Group entered into a lease agreement for its domicile, including equipment in Birkerød, Denmark. In 2021, the Company reduced the leased area for 2022 to primarily include a clean room. The buiilding is owned by Niels Erik Holm, who is a minority shareholder in the company. The lease agreement is concluded on market terms and contains no rights or terms related to the fact that Niels Erik Holm is a minority shareholder in the company. Rental deposits amount to DKK 68 thousand.

Since 2011, the Group entered into a supplier agreement with Innoventa Medica ApS, including the purchasing of goods related to the production of kits. The Group has entered into a Joint Ownership and Service Agreement with Innoventa Medica ApS under which the Group has been granted full co-ownership of Innoventa Medica ApS' quality management system ("**QMS**"). Innoventa Medica ApS is owned by Niels Erik Holm and Bo Jesper Hansen.

Niels Erik Holm and Bo Jesper Hansen is minority shareholders in the Company.

	2022 TDKK	2021 TDKK
Other related parties		
Debt to Innoventa Medica ApS	0	-145
Rental deposit	68	386

The Group is not ultimately controlled by any of the investors. See note 7 for additional related party transactions related to the remuneration paid to the Executive Management. In addition, Seed Capital Denmark II K/S, Novo Holdings A/S, Vækstfonden, MK Ventures ApS, North-East Health Care Investment ApS, Lauxera Growth I.S.L.P., Jan Struve and Bo Jesper Hansen all own more than 5%.

There have been no additional transactions between related parties in the 12-months period ended December 31, 2022 and the 12 months ended December 31, 2021 besides capital increases as described in note 15.

Terms and conditions of transactions with related parties

Amounts due to related parties are uncollateralized and interest free. There have been no guarantees provided or received for any related party receivables or payables. For the 12-months period ended December 31, 2022 and the 12-months period ended December 31, 2021, the Group has not recorded any impairment of receivables relating to amounts owed by related parties. There are no related party receivables at any of the balance sheet dates.

Transactions with key management

The Group has not granted any loans, guarantees, or other commitments to or on behalf of any of the members of the Board of Directors or key management personnel.

Other than the remuneration described in Note 7, no other significant transactions have taken place with key management personnel during the period presented herein.

Compensation paid to members of the Board of Directors

Compensation paid to members of the Board of Directors is classified as administrative expenses in the income statement. The following table lists compensation paid to members of the Board of Directors:

	2022 TDKK	2021 TDKK
Share-based compensation	0	0
Remuneration to the Board of Directors	916	980
Total compensation paid to the Board of Directors	**916**	**980**

Certain members of the Board of Directors have received warrants in the Parent Company (reference is made to note 9).

Transactions with shareholders and affiliates

There have been no transactions with shareholders or affiliates of shareholders during the 12-months period ending December 31, 2022 or the 12-months period ended December 31, 2021.

19. Subsequent events

In May 2023, a consortium consisting of new and existing investors agreed to a capital increase of DKK 77.8 million. The capital increase was paid out in May 2023 and introduces a new F-share class with liquidation preferences.

Other than the event disclosed above, there were no other events that were required to be reported or disclosed that have not already been included within these financial statements.

Parent company income statement and statement of comprehensive income

Note		2022 TDKK	2021 TDKK
5	Revenue	2,066	916
	Costs of sales	-2,960	-932
	Gross profit	**-894**	**-16**
6,9	Research and development expenses	-8,767	-9,834
6,9	Sales and marketing expenses	-6,995	-8,667
6,9	General and administrative expenses	-6,818	-5,590
	Operating loss	**-23,474**	**-24,107**
7	Financial income	9,159	6,933
8	Financial expenses	-37,286	-17,220
	Loss before tax	**-51,604**	**-34,394**
13	Income tax benefit	1,598	1,762
	Net loss for the period	**-50,003**	**-32,632**
	Other comprehensive loss to be reclassified to profit or loss in subsequent periods (net of tax):		
	Exchange differences on translation of foreign operations, net of tax	0	0
	Other comprehensive loss for the year, net of tax	**0**	**0**
	Total comprehensive loss	**-50,003**	**-32,632**
	Net loss attributable to:		
	Shareholders of Reapplix A/S	-50,003	-32,632
	Total	-50,003	-32,632
	Total comprehensive income attributable to:		
	Shareholders of Reapplix A/S	-50,003	-32,632
	Total	**-50,003**	**-32,632**

Note		2022 TDKK	2021 TDKK
	ASSETS		
	Non -current assets		
	Intangible assets	874	558
9	Property, plant and equipment	5,552	4,171
10	Investments in group entities	0	0
	Deposits	284	386
	Total non-current assets	**6,710**	**5,116**
	Current assets		
12	Inventories	811	800
11	Receivables from group entities	0	0
	Trade receivable	32	81
13	Corporation tax receivable	1,598	1,762
	Other receivables	504	483
	Prepayments	641	313
	Cash and cash equivalents	18,068	70,715
	Total current assets	**21,654**	**74,154**
	TOTAL ASSETS	**28,364**	**79,270**
	EQUITY AND LIABILITIES		
	Equity		
	Share capital	6,062	5,375
	Share premium	0	0
	Retained earnings	17,289	67,291
	Total equity	**23,351**	**72,666**
	Non-current liabilities		
	Lease liabilities	910	664
	Total non-current liabilities	**910**	**664**
	Current liabilities		
	Lease liabilities	551	600
	Bank debt	56	0
	Trade payables	619	657
	Other payables and accruals	2,876	4,683
	Total current liabilities	**4,102**	**5,940**
	Total liabilities	**5,012**	**6,604**
	TOTAL EQUITY AND LIABILITIES	**28,364**	**79,270**

Parent Company statement of changes in equity

	Note	Share capital TDKK	Share premium TDKK	Retained earnings TDKK	Total TDKK
Equity as of January 1, 2021		**4,355**	**0**	**37,314**	**41,669**
Net loss for the period		0	0	-32,632	-31,416
Other comprehensive income for the period		0	0	0	0
Total comprehensive income		**0**	0	**-32,632**	**-31,416**
Capital increase, cash injection		1,020	62,273	0	63,293
Transaction cost		0	0	0	0
Transfer to accumulated loss		0	-62,273	62,273	0
Share-based payment expense		0	0	337	337
Equity as of December 31, 2021		**5,375**	**0**	**67,292**	**72,666**

	Note	Share capital TDKK	Share premium TDKK	Retained earnings TDKK	Total TDKK
Equity as of January 1, 2022		5,375	**0**	**67,292**	72,666
Net loss for the period		0	0	-50,003	-50,003
Other comprehensive income for the period		0	0	0	0
Total comprehensive income		**0**	0	**-50,003**	**-50,003**
Capital increase, cash injection		687	0	0	687
Transaction cost		0	0	0	0
Transfer to accumulated loss		0	0	0	0
Share-based payment expense		0	0	0	0
Equity as of December 31, 2022		**6,062**	**0**	**17,289**	**23,351**

Parent Company cash flow statement

	Note	2022 TDKK	2021 TDKK
Operating activities			
Loss before tax		-51,601	-34,394
Reversal of financial income	6	-9,159	-6,933
Reversal of financial expenses	7	37,286	17.220
Reversal of fair value adjustment conversion option		0	0
Depreciation, amortization and impairment		2,883	1,820
Other non-cash items		-512	7,056
Adjustments to reconcile loss before tax to cash flows from operating activities			
Share-based payment expense		0	337
Change in inventories		-11	-366
Changes in receivables from group enterprises	10	-28,396	-16,883
Change in trade receivables		49	61
Change in other receivables		-21	1,080
Change in prepayments		-328	84
Change in trade payables		-38	-5,004
Change in other payables		-1,807	-1,691
Cash flows from taxes	12	1,762	1,896
Interest received	6	0	0
Interest paid	7	-227	-321
Net cash flow used in operating activities		**50,119**	**-36,038**
Investing activities			
Investment in property, plant and equipment		-5,063	-971
Investment in subsidiary	9	0	0
Deposits		-112	0
Net cash flow used in investing activities		**-5,175**	**-971**
Financing activities			
Capital contributions from shareholders		687	63,293
Bank loans		56	-48
Lease payment		-762	-990
Net cash provided by financing activities		**-19**	**62,255**
Net change in cash and cash equivalents		**-55,313**	**25,246**
Net foreign exchange differences		2,666	0
Cash and cash equivalents at the beginning of the period		70,715	45,469
Cash and cash equivalents at the end of the period		**18,068**	**70,715**

1. Accounting policies
2. Significant accounting judgments, estimates and assumptions
3. Standards issued but not yet effective
4. Going concern
5. Revenue from contracts with customers
6. Employee benefit expenses
7. Financial income
8. Financial expenses
9. Property, plant and equipment
10. Investment in subsidiaries
11. Receivables from group entities
12. Inventories
13. Income tax and deferred tax
14. Related party disclosures

Corporate information

Reapplix A/S (the "Parent Company") is a limited liability company incorporated and domiciled in Denmark. The registered office of Reapplix A/S is Bregnerødvej 133, st., 3460 Birkeroed, Denmark. The financial statements for the year ended December 31, 2022 were authorized for approval at the Annual General Meeting to be held on June 26, 2023, with a resolution of the Board of Directors on June 26, 2023.

1. Accounting policies

Basis of preparation

The financial statements of the Parent Company have been prepared in accordance with International Financial Reporting Standards, or IFRS, as adopted by the European Union. In prior years, the financial statements were prepared in accordance with the provisions applying to reporting class B enterprises under the Danish Financial Statements Act.

The consolidated financial statements have been prepared on a historical cost basis except for share-based payment. The parent company financial statements are presented in Danish Kroner, or DKK, which is the functional and presentation currency of the Parent Company. Where indicated, amounts are rounded to the nearest thousand, or TDKK.

As applicable to the Group, the Parent Company applies the same accounting policies as disclosed in the consolidated financial statements. Therefore, only accounting policies specific to the Parent Company or that differ from the accounting policies applied by the Group are disclosed in these notes to the financial statements. If an accounting policy is not specifically mentioned, the Group accounting policy is applied.

Investment in group entities

Investments in subsidiaries are measured in the parent company financial statements at the lower of cost or recoverable amount. Any distributed dividends are recognized in the income statement of the Parent Company.

Parent company notes

The notes applicable to the financial statements of the Parent Company are the same as those presented in the consolidated financial statements, except for those notes presented in this section.

2. Significant accounting judgments, estimates and assumptions

A description of Management's key accounting estimates and judgements is disclosed in the consolidated financial statements (note 2) and also apply to the Parent Company.

3. Standards issued but not yet effective

A description of relevant new IFRS standards are disclosed in the consolidated financial statements (note 3) and also apply to the Parent Company.

4. Going concern

A description of matters related to going concern are disclosed in the consolidated financial statements (note 4) and also apply to the Parent Company.

5. Revenue from contracts with customers

The Group's revenues are mainly derived from the 3C patch® system. The Group's primary customers include hospitals and clinics.

Reapplix A/S' registered office is situated in Denmark. The tables below illustrate revenue by geographical areas:

	2022 TDKK	2021 TDKK
Medical consumables (3CP^tm)		
Europe	460	608
United States of America (USA)	1,606	308
Total revenue	**2,066**	**916**

	2022 TDKK	2021 TDKK
Timing of revenue recognition		
Revenue from sale of Consumables at a point in time	2,066	916
Total revenue	**2,066**	**916**

Summary of key performance obligations related to revenue streams

The key performance obligations regarding sale of medical consumables are disclosed in the consolidated financial statements (note 5) and also apply to the Parent Company.

6. Employee benefit expenses

	2022 TDKK	2021 TDKK
Staff costs		
Wages/salaries	12,839	11,917
Share-based compensation expenses	0	337
Other social security costs	338	303
Other staff costs	0	168
Total staff costs	**13,177**	**12,725**
Average number of employees during the year	12	10
Total staff costs are included in the income statement as follows:		
Cost of sales	790	418
Research and development expenses	5,009	4,922
Sales and marketing expenses	3,689	3,516
General and administrative expenses	3,689	3,869
Total staff costs	**13,177**	**12,715**
Board of Directors remuneration		
Remuneration to the Board of Directors	916	980
Total Board of Directors remuneration	**916**	**980**

Refer to the consolidated financial statements for information about Executive Management remuneration.

7. Financial income

	2022 TDKK	2021 TDKK
Foreign exchange gain	5,634	5,003
Interest income, group entitites	3,521	1,930
Other interest income	4	0
Total financial income	**9,159**	**6,933**

8. Financial expenses

	2022 TDKK	2021 TDKK
Foreign exchange losses	0	16
Impairment losses on receivables from subsidiaries (note 11)	37,059	16,883
Interest expenses, lease liabilities	139	142
Other interest expenses	88	179
Total financial expenses	**37,286**	**17,220**

9. Property, plant and equipment

	Fixtures and fittings, other plant and equipment TDKK	Right-of-use assets TDKK	Demonstration equipment TDKK	Total TDKK
Cost at January 1, 2021	546	3,455	4,335	8,336
Additions	0	184	665	849
Disposals	0	0	0	0
Cost at December 31, 2021	546	3,639	5,000	9,185
Additions	355	821	4,319	5,495
Disposals	-437	-400	-2,778	-3,615
Cost at December 31, 2022	464	4,060	6,541	11,065
Accumulated depreciation at January 1, 2021	510	1,762	1,150	3,422
Depreciation expense	27	699	867	1,592
Write-down	0	0	0	0
Disposals	0	0	0	0
Accumulated depreciation at December 31, 2021	537	2,461	2,017	5,014
Depreciation expense	44	571	1,013	1,628
Write-down	0	1,182	0	0
Disposals	-437	-400	-1,475	-2,312
Accumulated depreciation at December 31, 2022	144	3,815	1,555	4,330
Total net carrying value at:				
December 31, 2021	9	1,178	2,984	4,171
December 31, 2022	320	246	4,986	6,735

9. Property, plant and equipment – continued –

Right-of-use assets

The Group has entered into a lease agreement for its domicile, including equipment in Birkeroed, Denmark

Depreciation expense

Depreciation expense is included in the income statement as follows:

	2022 TDKK	2021 TDKK
Cost of sales	124	122
Research and development expenses	600	586
Sales and marketing expenses	600	586
General and administrative expenses	305	299
Total depreciation expense	**1,628**	**1,592**

10. Investment in subsidiaries

	2022 TDKK	2021 TDKK
Cost at January 1	64	64
Additions during the year	0	0
Cost at December 31	**64**	**64**
Impairment losses at January 1	-64	-64
Impairment losses during the year	**0**	**0**
Impairment losses at December 31, 2022	**-64**	**-64**
Total net carrying value at:		
January 1	0	0
December 31	0	0

Subsidiary	Registered office	Ownership interest (%)	Share capital	Equity	Net loss
Reapplix Inc.	Delaware, USD	100	10 (TUSD)	-11,518 (TUSD)	-4,539 (TUSD)
Reapplix Ltd.	Nottingham, UK	100	0 (TGBP)	-37 (TGBP)	0 (TGBP)

11. Receivables from group entities

	2022 TDKK	2021 TDKK
Receivables from group entities at January 1	46,214	29,331
Transactions during the year	37,101	16,883
Receivables from group entities at December 31	**83,315**	**46,214**
Impairment losses at January 1	-46,214	-29,331
Impairment losses during the year	-37,101	-16,883
Impairment losses at December 31	**-83,315**	**-46,214**
Total net carrying value at:		
January 1	0	0
December 31	0	0

Receivables from group entities comprise receivable from subsidiaries, Reapplix Inc. and Reapplix Ltd.

Impairment
The Parent Company has recognised an allowance for expected credit losses (ECLs) on demand receivables from the subsidiaries, Reapplix Inc. and Reapplix Ltd. ECLs are based on the difference between the contractual cash flow due in accordance with the contract and the cash flow which the Parent Company expects to receive. The expected cash flow includes estimated cash flow to be recovered from the sale of the net asset in the subsidiary in case of default.

12. Inventories

	2022 TDKK	2021 TDKK
Raw materials and packaging	475	304
Finished goods	336	496
Total inventories	**811**	**800**

The total amount of inventories recognized as an expense in the 12-month periods ended at December 31, 2022 and December 31, 2021 amounted to DKK 378 thousand and DKK 408 thousand, respectively.

No write-down or reversal of write-down during the reporting periods.

13. Income tax and deferred tax

	2022 TDKK	2021 TDKK
Current tax on benefit on net loss	2,399	1,994
Adjustment to prior years	330	0
Tax credit research and development expenses	1,598	1,762
Change in unrecognized deferred tax before tax credit	-2,729	-1,994
Total income tax benefit for the period	**1,598**	**1,762**

13. Income tax and deferred tax – continued –

Reconciliation of effective tax rate to Danish statutory tax rate

	December 31, 2022 TDKK	December 31, 2021 TDKK
Net loss before tax	51,601	34,394
Corporate income tax rate in Denmark	22%	22%
Computed income tax benefit	**11,352**	**7,567**
Tax effect of:		
Adjustment to prior years	330	0
Other non-deductible expenses, including share-based compensation	-8,164	-4,339
Increased tax deductions on R&D expenses	479	529
Deferred tax asset not recognized	-2,399	-1,994
Total income tax benefit for the period	**1,598**	**1,762**

	2022 TDKK	2021 TDKK
Corporation tax receivable at January 1	1,762	1,896
Received corporate tax during the financial year	-1,762	-1,896
Calculated corporate tax current year	1,598	1,762
Transferred from non-current	0	0
Corporation tax receivable (current)	**1,598**	**1,762**

Deferred tax in the statement of financial position

	December 31, 2022 TDKK	December 31, 2021 TDKK
Deductible tax losses	21,468	19,896
Other temporary differences	1,045	218
	22,513	20,114
Deferred tax asset not recognized	-22,513	-20,114
Carrying amount	**0**	**0**

The Company had net tax loss carry-forwards in Denmark for income tax purposes of DKK 21,468 thousand and DKK 19,896 thousand as of December 31, 2022 and December 31, 2021.

Income tax benefit for the year includes a tax credit for research and development at the applicable tax rate under the Danish Corporate Income Tax Act.

The tax loss carry-forwards has no expiry date. The Company's ability to use tax loss carry-forwards in any one year is limited to 100% of the first DKK 8.9 million of taxable income plus 60% of taxable income above DKK 8.9 million.

The Company recognizes deferred tax assets, including the tax base of tax loss carry-forwards, if Management assesses that these tax assets can be offset against positive taxable income within a foreseeable future. Significant management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies. This judgment is made periodically after considering current facts and circumstances, budgets and business plans as well as the risks and uncertainty associated with the Company's ability successfully to commercialize and defend its intellectual property.

Significant judgment

The development of medical devices and launching such devices within the life sciences industry are subject to significant risks and uncertainties and there is no assurance that a medical device will be successfully developed or

13. Income tax and deferred tax – continued –

commericalized. As a result of this uncertainty and since the Company has reported significant losses since inception, has limited commercial products or revenues, Management has concluded that deferred tax assets should not be

recognized as of December 31, 2022 or at any other prior date. The tax assets are currently not deemed to meet the criteria for recognition as Management is not able to provide virtually certain evidence that taxable profits will be available in the future to utilize the benefit from the tax assets.

As of December 31, 2022, there are no tax audits in process nor has Management been notified of any pending tax audit.

14. Related party disclosure

The Parent Company's related parties comprise the subsidiary of the Parent Company, the significant shareholdes of the Company and their subsidiaries, the Executive Management, the Board of Directors and the close members of the family of these persons.

In 2022, the Parent Company transferred demonstration equipment of total DKK 1.6 million to the subsidiary, Reapplix Inc. Total receivable from the subsidiary as of December 31, 2022 amounts to DKK 0 million after impairment loss of DKK 37,1 million, and interest charged amounts to DKK 3.5 million for the 12-months period ended December 31, 2022.
Refer to note 11 for further information on impairment losses on receivables from group entities.

Refer to the consolidated financial statements for related party disclosure other than transactions with subsidiaries.